Literature DB >> 25044048

Potential changes to French recommendations about peri-prosthetic infections based on the international consensus meeting (ICMPJI).

M Ollivier1, E Senneville2, M Drancourt3, J N Argenson4, H Migaud5.   

Abstract

BACKGROUND: Despite the large volume of studies on the prevention, diagnosis, and treatment of peri-prosthetic infections, surgical practice often rests on limited scientific evidence in this field. The vast International Consensus Meeting on Peri-prosthetic Joint Infection (ICMPJI) held in 2013 produced robust recommendations. HYPOTHESIS: French consensus conference recommendations show no major differences with ICMPJI recommendations.
MATERIALS AND METHODS: The 207 recommendations developed by 300 experts at the ICMPJI were translated, and the translation was then examined by four reviewers, including 2 having participated in the consensus conference. The reviewers looked for any differences with French practices and recommendations.
RESULTS: Twenty-three major differences or innovations were identified compared to French recommendations and standard practice. Among them, pre-operative screening for nasal or urinary micro-organisms is performed routinely in France but should be reserved according to the ICMPJI for symptomatic patients and/or patients at high risk for infection. The ICMPJI emphasizes the role for the operating room environment as a vector for infection; more specifically, the operating lamp handle and suction cannula deserve close attention. A wound discharge persisting longer than 5-7 days requires irrigation and debridement. This procedure is effective only within the first 3 post-operative months and/or the first 3 weeks after symptom onset and must include exchange of all modular implants. The ICMPJI warns against both irrigation-debridement in fungal infections (suggesting two-stage prosthesis replacement) and one-stage replacement in patients with sinus tracts. The use of spacers (articulating at the knee) is recommended in the event of two-stage prosthesis replacement. DISCUSSION: The ICMPJI recommendations differed in many ways with French recommendations and standard practice. They can be expected to impact practices in France, although a point worth noting is that only 1 of the 207 recommendations received unanimous agreement by the conference experts (keeping operating room traffic to a minimum).
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Infection; Periprothetic infection guidelines; Total joint replacement

Mesh:

Substances:

Year:  2014        PMID: 25044048     DOI: 10.1016/j.otsr.2014.04.001

Source DB:  PubMed          Journal:  Orthop Traumatol Surg Res        ISSN: 1877-0568            Impact factor:   2.256


  4 in total

1.  Clindamycin Efficacy for Cutibacterium acnes Shoulder Device-Related Infections.

Authors:  Audrey Courdurié; Romain Lotte; Raymond Ruimy; Vincent Cauhape; Michel Carles; Marc-Olivier Gauci; Pascal Boileau; Johan Courjon
Journal:  Antibiotics (Basel)       Date:  2022-04-30

2.  Should we expand the indications for the DAIR (debridement, antibiotic therapy, and implant retention) procedure for Staphylococcus aureus prosthetic joint infections? A multicenter retrospective study.

Authors:  O Lesens; T Ferry; E Forestier; E Botelho-Nevers; P Pavese; E Piet; B Pereira; E Montbarbon; B Boyer; S Lustig; S Descamps
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-08-07       Impact factor: 3.267

3.  Bilateral One-Stage Revision of Infected Total Hip Arthroplasties: Report of Two Cases and Management of Antibiotic Therapy.

Authors:  Thomas Pommepuy; Adrien Lons; Kevin Benad; Eric Beltrand; Eric Senneville; Henri Migaud
Journal:  Case Rep Orthop       Date:  2016-01-19

4.  One-Stage Exchange Arthroplasty for Fistulizing Periprosthetic Joint Infection of the Hip: An Effective Strategy.

Authors:  Simon Marmor; Younes Kerroumi; Vanina Meyssonnier; Luc Lhotellier; Antoine Mouton; Wilfrid Graff; Valérie Zeller
Journal:  Front Med (Lausanne)       Date:  2020-10-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.